AngioDynamics, Inc. — FY2015 Form 10-K
Period: Fiscal year ended May 31, 2015; the filing also reports the fourth quarter ended May 31, 2015. The company designs, manufactures, and sells medical devices for peripheral vascular, vascular access, and oncology/surgery procedures. Figures are in U.S. dollars unless noted.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Net sales | $357.0 million | $354.4 million |
| Gross profit / margin | $176.9 million / 49.6% | $179.7 million / 50.7% |
| Operating income (loss) | ($1.0) million | $12.9 million |
| Net income (loss) | ($3.3) million; diluted EPS ($0.09) | $2.7 million; diluted EPS $0.08 |
| Cash from operating activities | $26.2 million | $24.7 million |
| Cash and cash equivalents | $18.4 million | $16.1 million |
| Marketable securities | $1.7 million | $1.8 million |
| Total debt | $137.7 million | $142.7 million |
| Working capital | $94.7 million | $85.0 million |
FY2015 sales rose about 1% year over year, or 2% excluding the declining supply agreement and on a constant-currency basis. International sales grew 9% at constant currency; U.S. sales were essentially flat. Product-category sales were $192.8 million in Peripheral Vascular, $107.9 million in Vascular Access, and $52.1 million in Oncology/Surgery. Operating cash flow exceeded net income, with depreciation and amortization and other noncash items contributing; investing activities used $13.3 million and financing activities used $10.5 million. The company reported $53.6 million of remaining revolver capacity and said available cash, operating cash flow, and that capacity should meet anticipated needs for at least 12 months. It was compliant with its credit-facility financial covenants at year-end.
Fourth-quarter sales were $90.9 million, versus $94.1 million a year earlier. Gross profit was $45.6 million versus $47.4 million; net loss was $0.8 million versus a $1.2 million loss, and diluted loss per share was $0.02 versus $0.03.
Material changes and unusual items
- Net loss and operating loss replaced the prior-year profits, despite modest sales growth. Gross margin fell 1.1 percentage points, with the Morpheus PICC inventory write-off and unfavorable currency effects among the pressures.
- Acquisition, restructuring, and other items rose to $26.6 million from $10.8 million. These included $9.1 million of fixed and long-term asset impairments, a $6.4 million NAMIC trademark impairment, recall-related costs, litigation costs, and restructuring expenses. The company also recorded an $8.2 million impairment of assets tied to its abandoned automated power injector project.
- The company voluntarily recalled and discontinued its Morpheus PICC product line after product complaints and an evaluation that did not identify a clear root cause. The reported year charge was $6.1 million, including $4.8 million of inventory write-offs.
- A $8.2 million gain from changes in the fair value of contingent consideration partly offset operating expenses; the contingent consideration liability was $47.4 million at year-end, with approximately $54.0 million in expected undiscounted future payments.
Outlook, commentary, and risks
Management gave no specific revenue or earnings guidance in the provided filing text. It stated that it anticipated a return to U.S. profitability in FY2016, and expects continued growth from BioFlo, AngioVac, and NanoKnife. The operational excellence program targets $15–$18 million of savings over three years; management also expects manufacturing efficiencies and slower expense growth than sales to support margin improvement. These are expectations, not guarantees.
- Regulatory and product risks: An FDA Warning Letter issued in November 2014 concerned design controls, packaging validation, product testing, and non-conforming product procedures. The company said it was working with the FDA to resolve outstanding matters. Failure to satisfy the FDA could lead to further enforcement or operating restrictions.
- Government investigations: DOJ subpoenas concern the historical LC Bead distribution relationship and alleged promotion of certain VenaCure EVLT products for uncleared indications. The company is cooperating and said it cannot predict the investigations’ scope or outcome.
- Litigation: Bard patent suits challenge certain implantable ports; potential loss was not considered estimable or probable, so no expense was recorded. The company reported favorable biolitec judgments, including a $74.9 million judgment against parent entities and an executive, but defendants appealed; recovery is uncertain.
- Debt and liquidity: Debt obligations, contingent acquisition payments, and credit covenants constrain flexibility. Approximately $1.7 million in auction-rate securities had failed auctions and may not be readily liquidated, although issuers were current on interest payments.
- Other exposures: Foreign-currency movements affected reported sales and gross profit; the company also identified reimbursement and pricing pressure, competition, supplier concentration, product liability, and regulatory compliance as significant risks.
- Restructuring and controls: The operational excellence program includes New York facility consolidation, planned reductions of approximately 80–100 positions, and $5.4 million of facility investment. Management and the auditor concluded internal control over financial reporting was effective at May 31, 2015; previously reported material weaknesses were stated to be remediated.
Most important facts for investors to verify
- Whether BioFlo, AngioVac, and NanoKnife growth can offset flat U.S. sales, currency pressure, and the decline in supply-agreement revenue.
- Whether margins recover after the Morpheus recall and the automated power injector and NAMIC impairments, and whether the targeted operational savings are achieved.
- The status and financial consequences of the FDA Warning Letter and both DOJ investigations, including any additional product actions.
- The outcomes and potential cash impact of Bard litigation and the appealed biolitec judgments; the filing does not establish that the favorable biolitec awards will be collected.
- Debt covenant headroom, refinancing or repayment requirements, and the timing and amount of contingent acquisition payments.
- The filing describes FY2016 profitability as an expectation, not formal quantified guidance; verify subsequent results against that expectation.